Researchers have found in a new study that patients receiving a combination of metformin and SGLT2 inhibitors experienced a ...

回望过去，细数SGLT2抑制剂跨越百年的成长历史1835年早在1835年，法国科学家克里斯托夫·彼得森首次从苹果树的根皮中分离出一种黄酮类化合物，命名为根皮苷（phlorizin），这是已知的第一个具有SGLT抑制活性的天然产物[1,2]。1886年 ...

Compared with vs DPP4 inhibitors, SGLT2 inhibitors reduce the risk for kidney and ureteral stones in patients with type 2 diabetes, including those with a stone history. Sodium-glucose cotransporter 2 ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

While the exact number of people with chronic kidney disease in South Africa is unclear, estimates suggest it could be as ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

与此同时，维生素 D 缺乏在人群中也较为普遍，即使在阳光充足的马来西亚也不例外。越来越多的证据表明，OSA 与维生素 D 缺乏之间存在着双向关联。此外，钠 - 葡萄糖协同转运蛋白 2 抑制剂（Sodium glucose transporter-2 inhibitor，SGLT2i）作为一种新型口服降糖药，除了能降低血糖外，还具有心血管保护作用。但目前关于维生素 D 补充剂以及 SGLT2i 在 ...

SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.

The following is a summary of "Impact of sodium-glucose cotransporter‐2 inhibitors in patients with recent versus previous ...

A widely used diabetes medication, SGLT2 inhibitors, has shown a surprising benefit for cancer patients—protecting their ...

Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 on evaluation and management of chronic kidney disease (CKD) in adults and children.